Evidence map›Paper›PMID 28078100›Full record

ReviewAsthma research and practice2017

Asthma costs and social impact.

Carlos Nunes, Ana Margarida Pereira, Mário Morais-Almeida

Registry-linked trialAbstract readReview
In one paragraph

Review in Asthma research and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06217419 (Proof of Concept of Remote Management of Chronic Inflammatory Airway Diseases for Patient Empowerment), which is not on this map. Cited by 321 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
321citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06217419 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Proof of Concept of Remote Management of Chronic Inflammatory Airway Diseases for Patient Empowerment

TypeinterventionalSponsorAzienda Ospedaliero Universitaria di SassariRan2024 to 2026Enrolled136ConditionsChronic Rhinosinusitis With Nasal Polyps, AsthmaArmsRadio Frequency IDentification (RFID) device
3 · Its place in the literature

Who cites it

321 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Biologic effectiveness increases with earlier biologic initiation after severe asthma onset.The journal of allergy and clinical immunology. Global · 2026
    Article
  12. Mechanisms and therapeutic strategies of asthma: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article

261 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Carlos NunesAlgarve Immunoallergy Center, Portimão, Portugal.
Ana Margarida PereiraAllergy Center, CUF Descobertas Hospital, Lisbon, Portugal.
Mário Morais-AlmeidaAllergy Center, CUF Descobertas Hospital, Lisbon, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent decades, both asthma prevalence and incidence have been increasing worldwide, not only due to the genetic background, but mainly because of the effect of a wide number of environmental and lifestyle risk factors. In many countries noncommunicable diseases, like asthma, are not yet considered a healthcare priority. This review will analyze and discuss disparities in asthma management in several countries and regions, such as access to healthcare human resources and medications, due to limited financial capacity to develop strategies to control and prevent this chronic disease. This review tries to explore the social and economic burden of asthma impact on society. Although asthma is generally accepted as a costly illness, the total costs to society (direct, indirect and intangible asthma costs) are difficult to estimate, mainly due to different disease definitions and characterizations but also to the use of different methodologies to assess the asthma socio-economic impact in different societies. The asthma costs are very variables from country to country, however we can estimate that a mean cost per patient per year, including all asthmatics (intermittent, mild, moderate and severe asthma) in Europe is $USD 1,900, which seems lower than USA, estimated mean $USD 3,100.

Indexed as

AsthmaBurdenControlCostsMorbidityMortalitySocio-economic

Identifiers

PMID28078100
PMCPMC5219738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.